Back to Search
Start Over
Correction to 'Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir'
- Source :
- ACS Pharmacology & Translational Science
- Publication Year :
- 2021
- Publisher :
- American Chemical Society, 2021.
-
Abstract
- The SARS-CoV-2 replication and transcription complex (RTC) comprising nonstructural protein (nsp) 2-16 plays crucial roles in viral replication, reducing the efficacy of broad-spectrum nucleoside analog drugs such as remdesivir and evading innate immune responses. Most studies target a specific viral component of the RTC such as the main protease or the RNA-dependent RNA polymerase. In contrast, our strategy is to target
- Subjects :
- Pharmacology
2019-20 coronavirus outbreak
Coronavirus disease 2019 (COVID-19)
business.industry
Ebselen
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Virology
Addition/Correction
chemistry.chemical_compound
chemistry
Replication (statistics)
Disulfiram
Medicine
Pharmacology (medical)
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 25759108
- Volume :
- 4
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- ACS Pharmacology & Translational Science
- Accession number :
- edsair.doi.dedup.....83ed2b416edaa0ad381e925d768385f4